MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Studying genes involved in abnormalities of the basal ganglia and iron homeostasis using gene co-expression network analysis

    M. van der Weijden, M. Tijssen, D. Verbeek (Groningen, Netherlands)

    Objective: To unravel the disease mechanisms underlying neurodegeneration with brain iron accumulation (NBIA) and to identify potential novel disease genes. Background: NBIA is clinically and…
  • 2018 International Congress

    Novel missense variants in KMT2B in segmental dystonia

    J. Ma, X.H. Wan (Beijing, China)

    Objective: To report and describe two novel missense mutations in KMT2B identified in two dystonia patients from China. Background: Recently, two independent groups have reported…
  • 2018 International Congress

    The Ultrastructural study of the effects of different types of chronic motor deficit on the morphology of limbic, extrapyramidal and neocortical regions of rat brain

    M. Zhvania, N. Lomidze, N. Gogokhia (Tbilisi, Georgia)

    Objective: To study the effect of chronic restraint stress and moderate motor deficit on the ultrastructure of central and lateral amygdalar nuclei, hippocampal CA1 and…
  • 2018 International Congress

    Toward optimized nonlinear deformation algorithms for subcortical DBS target regions in MRI

    S. Ewert, A. Horn, F. Finkel, N. Li, A. Kühn, T. Herrington (Berlin, Germany)

    Objective: 1. To evaluate and optimize subcortical accuracy of commonly used nonlinear deformation algorithms. 2. To optimize accuracy of automated atlas-based segmentation of the two…
  • 2018 International Congress

    Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2

    R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, USA)

    Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…
  • 2018 International Congress

    Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes

    M. Asanuma, I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, E. Nakayama, K. Shin, D. Yamamoto, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…
  • 2018 International Congress

    Botulinum toxin injection for Pisa syndrome in Parkinson’s disease

    CA. Artusi, M. Zibetti, P. Barbero, M. Busso, S. Bortolani, S. De Mercanti, P. Arnoffi, M. Fabbri, A. Merola, L. Lopiano (Torino, Italy)

    Objective: We sought to assess the clinical efficacy of Botulinum toxin (BoNT) injection for Pisa syndrome (PS) using a combined Magnetic Resonance Imaging (MRI)-, Ultrasonography…
  • 2018 International Congress

    Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

    R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

    Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone…
  • 2018 International Congress

    Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture

    J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina)

    Objective: To evaluate the effect of Mate leaves extracts on the survival and maturation of dopaminergic neurons in vitro. Background: Parkinson's disease (PD) is caused…
  • 2018 International Congress

    7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?

    E. Dellapina, F. Ory-Magne, A. Sommet, V. Rousseau, D. Devos, S. Thobois, L. Defebvre, C. Brefel-Courbon, JC. Corvol, O. Rascol, F. NS-PARK/FCRIN Network (Toulouse, France)

    Objective: (i) To collect all the levodopa equivalent doses (LED) formulae and references used in clinical trials in Parkinson’s disease (PD) since the publication of…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 177
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley